NxStage Medical, Inc. (NASDAQ:NXTM) President Joseph E. Turk, Jr. sold 1,000 shares of NxStage Medical stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $27.95, for a total value of $27,950.00. Following the sale, the president now directly owns 73,903 shares of the company’s stock, valued at approximately $2,065,588.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of NxStage Medical, Inc. (NASDAQ NXTM) traded up 0.07% during mid-day trading on Tuesday, hitting $27.99. The company’s stock had a trading volume of 832,264 shares. The stock’s market cap is $1.85 billion. NxStage Medical, Inc. has a 1-year low of $20.45 and a 1-year high of $30.80. The company has a 50-day moving average price of $26.61 and a 200-day moving average price of $25.92.
NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings data on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.03). NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The company had revenue of $92.20 million during the quarter, compared to the consensus estimate of $96.47 million. During the same period in the prior year, the business posted ($0.03) EPS. The company’s quarterly revenue was up .0% on a year-over-year basis. Analysts predict that NxStage Medical, Inc. will post ($0.04) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://sportsperspectives.com/2017/09/05/nxstage-medical-inc-nxtm-president-sells-27950-00-in-stock.html.
Several institutional investors have recently bought and sold shares of NXTM. SG Americas Securities LLC acquired a new position in shares of NxStage Medical during the 1st quarter worth about $140,000. Ameritas Investment Partners Inc. acquired a new position in shares of NxStage Medical during the 1st quarter worth about $148,000. Quantitative Systematic Strategies LLC acquired a new position in shares of NxStage Medical during the 2nd quarter worth about $203,000. Amalgamated Bank boosted its stake in shares of NxStage Medical by 7.1% during the 2nd quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock worth $210,000 after buying an additional 553 shares during the last quarter. Finally, Menta Capital LLC acquired a new position in shares of NxStage Medical during the 1st quarter worth about $212,000. Institutional investors own 93.20% of the company’s stock.
A number of research firms recently issued reports on NXTM. Jefferies Group LLC reduced their price objective on NxStage Medical from $38.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, May 10th. Zacks Investment Research raised NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research report on Thursday, August 10th. Canaccord Genuity cut NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 price objective for the company. in a research report on Monday, August 7th. BidaskClub cut NxStage Medical from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Finally, Craig Hallum began coverage on NxStage Medical in a research report on Tuesday, June 27th. They set a “buy” rating and a $32.00 price objective for the company. One investment analyst has rated the stock with a sell rating and nine have assigned a hold rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $30.25.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.